Pharmaceutical Registration in Honduras: ARSA, RTCA and Supplying a Shortage-Prone Market

Honduras is a market where the difference between what the regulations say and what actually happens on the ground is wider than in most of Central America — and pretending otherwise does nobody any favours.

It is also a market with real, persistent unmet need, a public system that buys in volume, and less exporter competition than the wealthier neighbours. For a supplier who can deal with the operational reality rather than the brochure version, that combination is genuinely attractive.

Honduras belongs to the Central American harmonised framework, so the dossier here is the dossier for five other countries.

Around ten and a half million people, with healthcare spending per head among the lower in the region and a public system that carries most of the burden.

Domestic manufacturing exists but is limited, concentrated in basic generics and common dosage forms. Practically everything specialised is imported — oncology, biologics, most injectables, paediatric specialities, and all advanced therapies.

Two population centres, Tegucigalpa and San Pedro Sula, hold most of the specialist capacity. A substantial share of the population lives outside them, often at distance and sometimes at altitude, which is a distribution problem more than a regulatory one but affects every supply decision you make.

Import dependence at this level means an exporter is not fighting for scraps against entrenched local production. The competition is other importers, and there are fewer of them than in Costa Rica or Panama.

Oncology. Entirely import-dependent and concentrated in a small number of referral centres. Demand is real and funding is constrained, which means price matters more than it does in wealthier markets — but so does reliability, because a treatment interruption in an oncology programme is not a commercial inconvenience.

Biosimilars. Arguably a better fit for Honduras than for richer neighbours, because the budget pressure that makes originator biologics unaffordable is exactly the pressure biosimilars answer. Expect proper comparability evidence to be required — a biosimilar is not treated as an ordinary generic.

Nutraceuticals and supplements. A growing private-sector category and generally a lighter registration route than medicines. Establish which category your product sits in before building a dossier; the medicine pathway is considerably more expensive and frequently unnecessary.

Biotech. Import-only. The binding constraint is cold chain and handling capability at the receiving end rather than regulatory willingness — verify the destination can actually store what you are sending before you send it.

Honduras experiences shortages of essential and life-saving medicines more frequently than most of its neighbours, and the causes are structural rather than accidental.

Public procurement and financing cycles. Where budget release, tender timing and payment run late, supply gaps follow. This is the dominant cause and it is not primarily a regulatory problem.

Single-source dependence. A market this size often supports one registered supplier per specialised product. Any interruption becomes a national shortage because there is no alternative already registered and ready.

Payment risk deterring suppliers. Where institutional payment cycles are long, some suppliers reduce exposure or withdraw. Shortages of this kind are financial in origin and tend to hit low-margin essentials hardest.

Distribution reach. A product available in Tegucigalpa is not necessarily available in a regional hospital. National-level stock figures can look adequate while specific facilities are out.

Categories that recur: oncology agents, anaesthetics and specialised injectables, paediatric formulations, insulin and chronic-disease medicines, and older essential products with thin margins.

For a supplier able to move quickly with complete documentation, these gaps are the most common entry point into an institutional relationship. They are also a responsibility — if you supply into a shortage you are part of a clinical situation, not just a transaction.

Medicines in Honduras are regulated by ARSA — Agencia de Regulación Sanitaria, which supervises, verifies and regulates products, services and establishments affecting public health.

ARSA handles sanitary registration of medicines, authorisation and inspection of establishments, import control and post-market surveillance, consolidating functions that were previously more dispersed across the health ministry.

ARSA has signed cooperation arrangements with neighbouring regulators including El Salvador's authority, covering exchange on controlled products, pharmacovigilance and legal frameworks. That regional cooperation is worth knowing about, because it signals where recognition and shared assessment may develop.

Confirm current procedure and requirements directly with ARSA. Consolidation of a regulator into a single agency tends to mean procedures continue evolving for some years afterwards.

Short answer: registration is required for commercial supply, with defined exceptional routes alongside it.

Placing a medicine on the Honduran market normally requires sanitary registration from ARSA. An import permit alone does not entitle you to sell.

Exceptional authorisations exist for genuine clinical need the registered market cannot meet — no registered equivalent, shortage, public health need, orphan products, named patient supply and trial material. Given how frequently shortages occur here, these routes are used more actively than in better-supplied markets.

The distinction that matters: exceptional import is legitimate for meeting a real gap, and it is not a way to trade continuously without registering.

RTCA format. Honduras applies the Central American Technical Regulation, harmonised across Guatemala, El Salvador, Honduras, Nicaragua, Costa Rica and Panama through COMIECO.

The scientific content overlaps heavily with the ICH Common Technical Document, so a CTD dossier is the right starting material — restructured and supplemented to RTCA requirements rather than filed unchanged.

ACTD is an ASEAN format and is not applicable here.

Build once for the region. Requirements are harmonised across six countries even though each registration is separate — that is the strongest economic argument for entering Honduras as part of a Central American programme rather than on its own.

WHO-GMP is the working baseline. A valid GMP certificate in WHO format from a recognised authority, supported by a CoPP, is the standard expectation for imported product.

Stronger credentials carry practical weight:

• EU-GMP — a strong signal, particularly for sterile products, biologics and biosimilars.
• US FDA inspection history — carries weight and supports reliance arguments.
• PIC/S membership of the certifying authority — increasingly recognised regionally.

Within the Central American framework, a certificate from a stringent regulatory authority may support safety and efficacy in defined cases even where that authority is not in the holder's country of origin.

In a market with recurring shortages and constrained budgets, there is a temptation to assume the lowest acceptable standard will do. That reads the situation wrongly. Constrained buyers are often more concerned about quality assurance, not less, because they have less capacity to absorb a failed consignment — and technical evaluation in tenders reflects that.

A locally established entity must hold the registration and be answerable to ARSA.

The standard trade-off applies. In Honduras there is an added consideration: the pool of capable, well-capitalised local partners is smaller than in Costa Rica or Panama, so the practical ability to change partner later is more limited than the contract might suggest.

Do more diligence than the market size appears to justify — on capitalisation and payment behaviour as much as on regulatory competence, given how much institutional payment cycles shape this market.

Expect the RTCA set: CoPP in WHO format legalised for use in Honduras, GMP certificate, manufacturing licence, finished product specification and validated method of analysis with validation reports, batch Certificate of Analysis, stability data for the applicable tropical zone, bioequivalence where required, Spanish labelling and insert to RTCA standards, and a legalised power of attorney.

Confirm the current list with ARSA before compiling.

RTCA harmonisation is the primary lever — each additional Central American filing costs far less than the first.

Reliance on established authorities. The eight PAHO Regional Reference Regulatory Authorities are ANMAT, ANVISA, Health Canada, ISP, INVIMA, CECMED, US FDA and COFEPRIS. An approval from one of these, or from a stringent authority such as the EMA, can carry part of the evidence burden.

Regional cooperation. ARSA's arrangements with neighbouring regulators suggest scope for shared assessment and recognition over time. Worth asking what currently applies before filing across the bloc in parallel.

Reliance is discretionary and varies by product category.

Deficiency cycles determine elapsed time. In a market where administrative capacity is stretched, a complete and correctly formatted first submission is worth considerably more than an early one.

Registrations run for a fixed term and require renewal. Track renewals across the RTCA bloc together.

Build realistic contingency into commercial commitments. Promising an institution a delivery date that depends on a registration completing to schedule is a way to damage a relationship you have just started.

Honduras is a party to the Hague Apostille Convention, as is India, so apostille rather than full consular legalisation will generally apply to public documents. Confirm before arranging consular appointments.

Standing issues: CoPP validity expiring mid-process, commercial documents needing notarisation to qualify for apostille, certified Spanish translation to local formal requirements, and exact name consistency across all documents.

Filing across the bloc, sequence certificate issuance so one CoPP validity window covers as many applications as possible.

Exceptional import routes cover no registered equivalent, shortage or supply interruption, public health need or declared emergency, orphan and rare disease products, and clinical trial material.

Standard conditions: consignment-specific authorisation against a stated justification, applied for by the importing institution or licensed importer, and not a substitute for registration where supply is continuous.

Honduras uses these routes more than most Central American markets, because shortages are more frequent. That creates a genuine commercial opening — a supplier who responds within days with a complete document pack becomes the one an institution calls next time.

It also creates an obligation worth stating. Supplying into a shortage means a hospital is relying on you for a treatment that is already unavailable. If you cannot hold the delivery date, say so at the outset rather than accepting the order and hoping. In this market, reliability is a more durable advantage than price.

Confirm current conditions with ARSA.

An unregistered medicine may be imported for an individually identified patient, on a treating physician's responsibility, where no suitable registered alternative exists.

Typically required: prescription naming the patient, clinical justification, authority authorisation before shipment, quantity limited to the treatment course, batch CoA and provenance.

Compassionate use and expanded access for clinical-stage products sit under their own framework.

The practical challenge in Honduras is the final leg. Specialist care concentrates in Tegucigalpa and San Pedro Sula while patients are distributed nationally, and cold chain capability outside the main centres is limited. A consignment landing quickly in the capital may still face a demanding onward journey.

Ask about the delivery point and the receiving facility's storage capability before committing to a timeline — not after.

Further reading: our global guide to named patient import programmes, our named patient supply service, and our cold chain logistics page.

Public demand runs through the Ministry of Health and through IHSS (Instituto Hondureño de Seguridad Social), the social security institute. They purchase separately.

A valid registration is generally required to bid.

Two realities to price in. Procurement is highly price-sensitive, and payment cycles can be long — the working capital cost of institutional supply is a real component of your margin here, not a footnote. Suppliers who model only the unit price and ignore the receivable are the ones who conclude after two years that the market does not work.

The PAHO Strategic Fund deserves particular attention in Honduras. It is the Pan American Health Organization's pooled-procurement mechanism for member states that have signed an agreement with the Organization, with eligibility resting on WHO Prequalification at tender opening or approval by regulatory authorities of regional reference rather than national registration in each country. For a WHO Prequalified product, this can be both a faster route in and a more secure payment position than direct institutional supply. Confirm current criteria with PAHO.

Our government and institutional tender supply page covers the technical file.

The honest list of what makes this market hard:

• Payment cycles. The single most cited difficulty. Long institutional payment timelines tie up working capital and are the main reason suppliers withdraw.
• Customs clearance delays, which matter enormously for temperature-sensitive product — a shipper qualified for the scheduled transit is not qualified for the realistic one.
• Distribution beyond the two main cities, where cold chain and road infrastructure are limiting.
• Budget-driven demand volatility. Orders can pause when funding does, which makes forecasting difficult and inventory planning risky.
• Partner capitalisation. A smaller pool of well-funded local partners, in a market where partners carry receivable risk.
• Price sensitivity against quality expectations. Buyers want stringent-authority credentials and the lowest price, and that tension does not resolve itself.
• Tropical stability data — temperate-market data will not support labelling here.
• Expired or mismatched certificates, the regional constant.

The Honduran conclusion: if you hold WHO Prequalification, look hard at the Strategic Fund before anything else. It addresses the registration burden and the payment risk in one move, and those are the two things that most often defeat exporters here.

Model the receivable, not just the price. Working capital is the thing that decides whether Honduras works for you, and it is the factor most consistently left out of entry analysis.

If you have WHO Prequalification, start with the Strategic Fund. Different route, different counterparty, different payment profile.

Enter as part of a Central American programme. One RTCA dossier across six countries is what makes the economics work; Honduras alone is a harder case.

Be careful what you promise. This is a market where supply reliability is scarce and therefore valuable — and where failing to deliver into a shortage does more damage than never having quoted.

Check the receiving facility's storage before shipping anything temperature-sensitive outside the main cities.

Not legal advice. Confirm current requirements with ARSA and take local advice before committing funds.